CollPlant Biotechnologies announced on June 9, 2025, the expansion of its agreement with STEMCELL Technologies, a biotechnology company specializing in cell culture media and tools. The amended agreement broadens the use of CollPlant's proprietary rhCollagen.
Under the expanded terms, CollPlant's rhCollagen will now be utilized beyond research applications to include clinical development and commercial-scale manufacturing. This signifies a significant step towards integrating CollPlant's technology into broader therapeutic and commercial domains.
This milestone highlights the evolving needs of the life sciences market and the strength of CollPlant's novel technology, which offers a viable alternative to animal-sourced materials. The expansion aligns with growing industry priorities around safety, consistency, and ethical sourcing, positioning CollPlant for increased market penetration.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.